Dementia and Major Neurocognitive Disorders: Some Lessons Learned One Century after the First Alois Alzheimer’s Clinical Notes

Donatella Rita Petretto 1,*, Gian Pietro Carrogu 1,2, Luca Gaviano 1,2, Lorenzo Pili 1,2 and Roberto Pili 2

Over 100 years ago, Alois Alzheimer presented the clinical signs and symptoms of what has been later called “Alzheimer Dementia” in a young woman whose name was Augustine Deter [1–3]. Alois Alzheimer described Augustine’s clinical history until her early death in 1906, and he focused his attention on a variety of impairments in functional domains in different phases of the disorder (first memory impairments, then delusions of husband’s adultery and sleeping disorders, then impairments in other cognitive domains and on consciousness). Alois Alzheimer studied her brain and described some peculiar clinical and pathological findings [1–3].

The word “dementia” was used for the first time by Pinel in 1797 [1,2], but there have been clinical notes on this disorder since ancient times. Some years later, the Alois Alzheimer’s clinical description of Augustine and after the endorsement of Kraepelin, who used for the first time the terminology “Alzheimer disease” in his 8th edition of Handbook of Psychiatry, dementia received a great attention from clinicians and from researchers. “Alzheimer Dementia” is now the most frequent and also the most known dementia all over the world [1–3].

Recently, international diagnostic criteria proposed to modify the name “dementia” with the string “major neurocognitive disorder” (MNCD) [4] aiming to reduce the negative stigma associated with the previous name and with his original meaning from the Latin word “demens” (“without mind”) [1]. Since the study of Alzheimer, MNCD gained a great attention in clinical and research field, and nowadays it is considered a major public health priority, due to its prevalence and incidence all over the world: over 6% in people older than 65 years, with an increasing of prevalence each five years of age and with an even higher prevalence in developing countries [5].

In this editorial, we aim to highlight some lessons learned in this field and to discuss some open questions since the first description of Alzheimer.

There are two main topics of interest: diagnosis/differential diagnosis, treatment and cure/care of people with MNCD. About diagnosis, in the last twenty years, there has been an increase of neuropathological findings and of neuroimaging findings at the base of the diagnosis of various forms of MNCDs, also with some overlapping between apparently different clinical conditions [6–15]. There has also been an increase of neuropsychological findings in different phases of the clinical history of various forms of MNCD [7,9,16–21]. As main consequences of these aspects, nowadays we know at least over 10 types of MNCDs and we know that there are at least three different kinds of clinical onsets: cognitive signs and symptoms, motor signs and symptoms and psychopathological/affective signs and symptoms [22,23]. There is now a general agreement about the role of recent and remote clinical history, the role of the description of onset signs and symptoms and the
role of neuropsychological and psychopathological assessment [18–21,24]. Again, there is a
general agreement on the need to correlate clinical manifestations with neuropathological
and neuroimaging findings, even in the early phases of the disorder [7,16]. We also
know more about the relationship between MNCD and mild neurocognitive disorders
(previously named “mild cognitive impairment”), also with reference to the kind of onset
signs and symptoms and with reference to clinical trajectories between them [22,23,25,26].
In recent years, differential diagnosis in MNCD has improved thanks to the integration of
all currently available knowledge, but further research is still needed [22,23].

About the treatment, there is a general agreement on the need to integrate phar-
caceutical and not pharmacological treatments and there are increasing data on the
effectiveness of some non-pharmacological approaches, like those based on specific cogni-
tive training [27–29]. As there are increasing findings on the overlapping between vascular
MNCD and other kinds of MNCD, the roles of eating, health habits, diet and physical
activities received great attention in longitudinal and retrospective studies in the field of
primary and secondary prevention of MNCD [30,31]. Again, further research is needed
also in the field of treatment.

There are still some open questions. Taking into account a worldwide approach, only
50% of people with MNCD received a correct diagnosis and adequate care and support; in
developing countries, only 10% of people with MNCD are correctly supported [5]. Interna-
tional data showed an increasing prevalence of MNCD, mainly due to the relationship
between constitutional/genetics factors [32–34], unhealthy habits [30,31] and negative
environmental factors [35–41]. Moreover, the progressive ageing of the population has a
central role in the increasing of prevalence, as the prevalence of MNCD is higher in higher
ages [42]. Further research is needed on etiologies of MNCD and on the effectiveness of
treatments and primary and secondary prevention interventions [5].

Moreover, taking into account individual experiences of people with MNCD, it is
necessary to understand their unmet needs during the different stages of diseases, and it
is mandatory to discuss how to increase and to support their quality of life and how to
sustain their autonomy and independence [21,43–51]. There is still an open debate on the
need to support people with MNCD in living in their homes and in their environments
and, when they choose to live in medium and long-term facilities, it is important to
support them also in this experience [51–54]. Negative experiences and risks related to
institutionalization are debated, also taking into account the current experiences during the
COVID-19 pandemic [55–59]. Moreover, the role of self-advocacy’s and families’ association
is crucial. It is also necessary to better understand social costs on individuals and on other
family members [60] and how to support caregivers and family members to adapt to
caregiving and to prevent negative effects of family burden [5,54,61]. There also some
ethical aspects related to the overall effect of MNCD on individual’s life and other ethical
aspects related to advance care planning and end-of-life care [51,62–64].

In summary, in this editorial, we aim to discuss some lessons learned in the last
century on MNCD, but we also propose some open questions that require higher attention
in the next research in the field. Alzheimer showed great clinical comprehension, clinical
intuition and foresight into detailing Augustine’s clinical history during her disorder: his
clinical notes on the effects on different cognitive and behavioral domains of her life are
consistent with the clinical approach confirmed by recent research. He has been a pioneer
in this field. In about a century after the Alzheimer’s notes, clinicians and researchers
have gained great knowledge in the field of MNCD and we believe that great work will be
done in the near future. A trans-disciplinary approach, based on the cooperation between
neurologists, neuroradiologists and other physicians, neuropsychologists and other health
professionals, is crucial to gain more detailed knowledge in the field of MNCD, and
the cooperation between different fields of study is mandatory. As MNCD affects all the
domains of people’s life and it also affects different aspects of the Self and the project in
life, we believe that a person-centered approach is needed, with a central role of the people
with MNCD.
Author Contributions: All the authors equally contributed to the design of the study. All authors have read and agreed to the published version of the manuscript.

Funding: This study is supported by DRP’s personal research grant from the University of Cagliari and RP’s grant from Fondazione di Sardegna.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Cipriani, G.; Dolciotti, C.; Picchi, L.; Bonuccelli, U. Alzheimer and his disease: A brief history. Neurol. Sci. 2011, 32, 275–279. [CrossRef] [PubMed]
2. Yang, H.D.; Kim, D.H.; Lee, S.B.; Young, I.D. History of Alzheimer’s disease. Dement. Neurocogn. Disord. 2016, 15, 115–121. [CrossRef] [PubMed]
3. Knapman, D.S.; Petersen, R.C.; Jack, C.R. A brief history of “Alzheimer disease”: Multiple meanings separated by a common name. Neurology 2019, 92, 1053–1059. [CrossRef] [PubMed]
4. APA American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM5, 5th ed.; American Psychiatric: Washington, DC, USA, 2013.
5. World Health Organization. Dementia: A Public Health Priority; World Health Organization: Geneva, Switzerland, 2016.
6. Kim, J; Kim, Y.-K. Inflammatory biomarkers in AD: Implications for diagnosis. Curr. Alzheimer Resour. 2020, 17, 1–12. [CrossRef]
7. Frisoni, G.B.; Fox, N.C.; Jack, C.R., Jr.; Scheltens, P.; Thompson, PM. The clinical use of structural MRI in Alzheimer disease. Nat. Rev. Neurol. 2010, 6, 67–77. [CrossRef] [PubMed]
8. Knight, M.J.; Mc Cann, N.; Kauppinen, R.A.; Coulthard, E.J. Magnetic Resonance Imaging to detect early molecular and cellular changes in Alzheimer’s Disease. Front. Aging Neurosci. 2016, 8, 139. [CrossRef] [PubMed]
9. Chapuis, P.; Sauvee, M.; Medici, M.; Serra, A.; Banciu, E.; Moreau-Gaudry, A.; Moureau, O.; Krainik, A. Morphological and Neuropsychological patterns in patients suffering from Alzheimer’s disease. Diagn. Neurowadiol. 2016, 58, 455–466.
10. Mainta, I.C.; Perani, D.; Delattre, B.M.; Assal, F.; Haller, S.; Vargas, M.I.; Zekry, D.S.; Frisoni, G.B.; Zaidi, H.; Ratib, O.; et al. FDG PET/MR Imaging in Major Neurocognitive Disorders. Curr. Alzheimer Res. 2017, 14, 186–197. [CrossRef]
11. Brooks, D.J. Future Imaging in Dementia. Semin. Nucl. Med. 2020, in press. [CrossRef]
12. Koriath, C.A.M.; Kenny, J.; Ryan, N.S.; Rohrer, J.D.; Schott, J.M.; Houlden, H.; Fox, N.C.; Tabrizi, S.J.; Mead, S. Genetic testing in dementia—Utility and clinical strategies. Nat. Rev. Neurol. 2020. [CrossRef]
13. Ricci, M.; Cimini, A.; Chiaravalloti, A.; Filippi, L.; Schillaci, O. Positron Emission Tomography (PET) and Neuroimaging in the Clinical use of structural MRI in Alzheimer disease. Nat. Rev. Neurol. 2010, 6, 67–77. [CrossRef] [PubMed]
14. Chélatel, G.; Arbizu, J.; Barthel, H.; Garibotto, V.; Law, I.; Morbelli, S.; van de Giessen, E.; Agosta, F.; Barkhof, F.; Brooks, D.J.; et al. Amyloid-PET and (18)F-FDG-PET in the diagnostic investigation of Alzheimer’s disease and other dementias. Lancet Neurol. 2020, 19, 951–962. [CrossRef]
15. Frisoni, G.B. Alzheimer disease: Biomarker trajectories across stages of Alzheimer disease. Nat. Rev. Neurol. 2012, 8, 299–300. [CrossRef] [PubMed]
16. Allen, C.L.; Behrman, S.; Ebmeier, K.; Valkanova, V. Diagnosis early decline: When, how, and for whom? Maturitas 2017, 96, 103–108. [CrossRef]
17. Lu, P.H.; Lee, G.J. The Role of Neuropsychology in the Assessment of the Cognitively Impaired Elderly. Neurol. Clin. 2017, 35, 191–206. [CrossRef]
18. Devineni, B.; Onyike, C.U. Young-Onset Dementia Epidemiology Applied to Neuropsychiatry Practice. Psychiatr. Clin. N. Am. 2015, 38, 233–248. [CrossRef]
19. Onyike, C.U. Psychiatric Aspects of Dementia. Continuum 2016, 22, 600–614. [CrossRef] [PubMed]
20. Johnen, A.; Bertoux, M. Psychological and Cognitive Markers of behavioral variant of Frontotemporal dementia: A clinical neuropsychologist’s view on diagnostic criteria and beyond. Front. Neurol. 2019, 10, 594. [CrossRef] [PubMed]
21. Vos, S.J.; van Rossum, I.A.; Verhey, F.; Knol, D.L.; Seininen, H.; Wahlund, L.O.; Hampel, H.; Isolak, M.; Minthon, L.; Frisoni, G.B.; et al. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology 2013, 80, 1124–1132. [CrossRef]
26. Marizzoni, M.; Ferrari, C.; Jovicich, J.; Albani, D.; Babiloni, C.; Cavaliere, L.; Didic, M.; Forloni, G.; Galluzzi, S.; Hoffmann, K.T.; et al. Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer’s Disease: Structural Brain Biomarkers. Pharma Cog Consortium. J. Alzheimers Dis. 2019, 69, 3–14. [CrossRef] [PubMed]

27. Verreault, P.; Turcotte, V.; Ouellet, M.-C.; Robichaud, L.A.; Hudon, C. Efficacy of cognitive-behavioural therapy interventions on reducing burden for caregivers of older adults with a neurocognitive disorder: A systematic review and meta-analysis. Cogn. Behav. Ther. 2020, 1–28. [CrossRef] [PubMed]

28. Yao, S.; Liu, Y.; Zheng, X.; Zhang, Y.; Ciu, S.; Tang, C.; Lu, L.; Xu, N. Do nonpharmacological interventions prevent cognitive decline? A systematic review and meta-analysis. Transl. Psychiatry 2020, 10, 19. [CrossRef] [PubMed]

29. Chan, J.Y.C.; Chan, T.K.; Kwok, T.C.Y.; Wong, S.Y.S.; Lee, A.T.C.; Tsai, K.K.F. Cognitive training interventions and depression in mild cognitive impairment and dementia: A systematic review and meta-analysis of randomized controlled trials. Age Ageing 2020, 49, 738–747. [CrossRef] [PubMed]

30. Petersson, S.D.; Philippou, E. Mediterranean Diet, Cognitive Function, and Dementia: A Systematic Review of the Evidence. Adv. Nutr. 2016, 7, 889–904. [CrossRef] [PubMed]

31. Limongi, F.; Siviero, P.; Bozanic, A.; Noale, M.; Veronese, N.; Maggi, S. The Effect of Adherence to the Mediterranean Diet on Late-Life Cognitive Disorders: A Systematic Review. J. Am. Med. Dir. Assoc. 2020, 21, 1402–1409. [CrossRef]

32. Ramos, C.; Aguillon, D.; Cordano, C.; Lopera, F. Genetics of dementia: Insights from Latin America. Dement. Neuropsychol. 2020, 14, 223–236. [CrossRef]

33. de Frutos-Lucas, J.; Frost, N.; Ericksson, K.I.; Serrano, J.M.; Maestu, F.; Laws, S.M.; Brown, B.M. Does APOE genotype moderate the relationship between physical activity, brain health and dementia risk? A systematic review. Ageing Res. Rev. 2020, 64, 101173. [CrossRef] [PubMed]

34. Kwok, J.B.; Loy, C.T.; Dobson-Stone, C.; Halliday, G.M. The complex relationship between genotype, pathology and phenotype in familial dementia. Neurobiol. Dis. 2020, 145, 105082. [CrossRef] [PubMed]

35. Fox, D.A.; Grandjean, P.; De Groot, D.; Paule, M.G. Developmental origins of adult diseases and neurotoxicity: Epidemiological and experimental studies. Neurotoxicology 2012, 33, 810–816. [CrossRef] [PubMed]

36. Delgado-Saborit, J.M.; Guercio, V.; Gowers, A.M.; Shaddick, G.; Fox, N.C.; Love, S.M. A critical review of the epidemiological evidence of effects of air pollution on dementia, cognitive function and cognitive decline in adult population. Sci. Total Environ. 2020, 757, 143734. [CrossRef]

37. Tham, R.; Schikowski, T. The Role of Traffic-Related Air Pollution on Neurodegenerative Diseases in Older People: An Epidemiological Perspective. J. Alzheimers Dis. 2020. [CrossRef]

38. Landrigan, P.J.; Stegman, J.J.; Fleming, L.E.; Raps, H.; Rampal, P. Human Health and ocean pollution. J. Cent. Nerv. Syst. Dis. 2020, 8, 117957351984387. [CrossRef]

39. Grandjean, P.; Landrigan, P.J.; Stegman, J.J.; Fleming, L.E.; Raps, H.; Rampal, P. Developmental origins of adult diseases and neurotoxicity: Epidemiological and experimental studies. Neurotoxicology 2012, 33, 810–816. [CrossRef] [PubMed]

40. Aloizou, A.M.; Sioka, V.; Sapouni, E.M.; Sita, N.; Limpas, I.; Brotis, A.G.; Rakitskii, V.N.; Burykina, T.I.; Aschner, M.; Bogdanos, D.P.; et al. Parkinson’s disease and pesticides: Are microRNAs the missing link? J. Alzheimers Dis. 2020, 74, 143734. [CrossRef] [PubMed]

41. Limongi, F.; Siviero, P.; Bozanic, A.; Noale, M.; Veronese, N.; Maggi, S. The Effect of Adherence to the Mediterranean Diet on Late-Life Cognitive Disorders: A Systematic Review. J. Am. Med. Dir. Assoc. 2020, 21, 1402–1409. [CrossRef]

42. Pili, R.; Petretto, D.R.; et al. Parkinson’s disease and pesticides: Are microRNAs the missing link? J. Alzheimers Dis. 2020, 74, 143734. [CrossRef] [PubMed]

43. Verreault, P.; Turcotte, V.; Ouellet, M.-C.; Robichaud, L.A.; Hudon, C. Efficacy of cognitive-behavioural therapy interventions on reducing burden for caregivers of older adults with a neurocognitive disorder: A systematic review and meta-analysis. Cogn. Behav. Ther. 2020, 1–28. [CrossRef] [PubMed]

44. Aravena, J.; Gajardo, J.; Gitlin, L. Non-Pharmacological Interventions for Caregivers of People with Dementia in Latin America: A Systematic Review. Innov. Aging 2020, 4, 152. [CrossRef]

45. McKnight, S.; Hacks, N. Toxic-induced Parkinsonism. Neurol. Clin. 2020, 38, 853–865. [CrossRef]

46. Pili, R.; Petretto, D.R. La Longevità nel Benessere: Sfide Presenti e Future; Edizioni Aracne: Roma, Italy, 2019.

47. Hughes, S.E.; Woods, B.; Algar-Skaife, K.; Jelley, H.; Jones, C.H. A Collaborative Approach: Care Staff and Families Working Together to Safeguard the Quality of Life of Residents Living With Advanced Dementia. J. Cent. Nerv. Syst. Dis. 2019, 11, 117957351984387. [CrossRef] [PubMed]

48. Hazzan, A. Quality of Care Provided by Family Caregivers of Older People with Dementia: Measurement and Interpretations. Innov. Aging 2020, 4, 152. [CrossRef]

49. Aravena, J.; Gajardo, J.; Gitlin, L. Non-Pharmacological Interventions for Caregivers of People with Dementia in Latin America: A Review. Innov. Aging 2020, 4 (Suppl. S1), 275–276. [CrossRef]

50. Hu, M.; Grunin, L.; Wu, B. Chinese American Caregivers of Older Adults With Alzheimer’s Disease and Other Dementias: A Scoping Review. Innov. Aging 2020, 4, 160. [CrossRef]

51. Baker, Z.; Jutkowitz, E.; Gaugler, J. A Systematic Review of Interventions That Reduce Family and Friend Caregiving Time. Innov. Aging 2020, 4 (Suppl. S1), 350. [CrossRef]

52. Raj, A.; Kosatsky, T. Public health should promote co-operative housing and cohousing. Can. J. Public Health 2019, 110, 121–126. [CrossRef] [PubMed]

53. Clemmensen, T.H.; Laxauridsen, H.H.; Andersen-Ranberg, K.; Kristensen, H.K. Informal carers’ support needs when caring for a person with dementia—A scoping literature review. Scand. J. Caring Sci. 2020. [CrossRef] [PubMed]
55. Cai, Y.; Wang, J.; Wu, B. COVID-19 Infections in Long-Term Care Facilities in Wuhan, China: Challenges and Lessons. *Innov. Aging* 2020, 4 (Suppl. S1), 18. [CrossRef]

56. Petretto, D.R.; Pili, R. Ageing and COVID-19: What is the role for elderly people? *Geriatrics* 2020, 5, 25. [CrossRef] [PubMed]

57. Carta, M.G.; Orrù, G.; Scano, A.; Coghe, F.; Nunnari, G.; Facchini, G.; Numis, F.G.; Berretta, M. In the face of the SARS-CoV-2 outbreak, do people suffering from oncological disease need specific attention? *Eur. Rev. Med. Pharmacol. Sci.* 2020. [CrossRef]

58. Carta, M.G.; Romano, F.; Orrù, G. The True Challenges of the Covid-19 Epidemics: The Need for Essential Levels of Care for All. *Open Respir. Med. J.* 2020, 14, 8–9. [CrossRef]

59. Ryoo, N.; Pyun, J.M.; Baek, M.J.; Suh, J.; Kang, M.J.; Wang, M.J.; Youn, Y.C.; Yang, D.W.; Kim, S.Y.; Park, Y.H.; et al. Coping with Dementia in the Middle of the COVID-19 Pandemic. *J. Korean Med. Sci.* 2020, 35, e383. [CrossRef]

60. Connolly, S. Economics of dementia: A review of methods. *Dementia* 2020, 19, 1426–1440. [CrossRef]

61. Lindeza, P.; Rodrigues, M.; Costa, J.; Guerreiro, M.; Rosa, M.M. Impact of dementia on informal care: A systematic review of family caregivers’ perceptions. *BMJ Supportive Palliat. Care* 2020, 1–12. [CrossRef]

62. Sellars, M.; Chung, O.; Nolte, I.; Sinclair, C.; Detering, K.M. Perspectives of people with dementia and carers on advance care planning and end-of-life care: A systematic review and thematic synthesis of qualitative studies. *Palliat. Med.* 2019, 33, 274–290. [CrossRef]

63. Stavert, J. Respecting the autonomy of the living and the dying. *J. Integr. Care* 2020, 28, 379–385. [CrossRef]

64. Allen, W. Medical Ethics issues in Dementia and End of life. *Curr. Psychiatr. Rep.* 2020, 22, 31. [CrossRef] [PubMed]